The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Improving Hepatitis B Vaccination Rates among At-risk Children and Adolescents with Inflammatory Bowel Disease
Pediatr Qual Saf. 2022 Jun 23;7(4):e570. doi: 10.1097/pq9.0000000000000570.eCollection 2022 Jul-Aug.
1Department of Pharmacy, Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
2Division of Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
3General Pediatrics Residency Program, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
4Center for Clinical Excellence, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
5Division of Infectious Diseases and Host Defense Program, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio.
Abstract
Patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor alpha inhibitors (TNFai) may be at higher risk for hepatitis B virus (HBV) infection. We conducted a quality improvement (QI) initiative to improve HBV vaccination rates in seronegative children with IBD.
Methods: This QI initiative implemented an HBV vaccination strategy from September 2018 to March 2020 in patients with newly diagnosed IBD with hepatitis B surface antibody (HBsAb) <10 mIU/mL. The project aimed to (1) increase HBV vaccination rates in seronegative patients and (2) document immunogenicity after completing a three-dose vaccine series. Outcome measures included the percentage of seronegative patients who received HBV vaccines (dose 1 and three-dose series). Interventions included applying a standardized vaccination protocol, and creating a vaccine workflow in two clinical areas, previsit planning and stakeholder engagement.
Results: One hundred seventy-four children and adolescents with IBD were evaluated during the study period, and 132 (76%) were HBsAb negative. After plan-do-study-act (PDSA) 1, the proportion of eligible patients who received HBV vaccine dose 1 increased from a baseline of 7% to 100% and was sustained for over 12 months. During PDSA 2, the proportion of patients completing the three-dose vaccine series improved from a baseline of 0% to 82% (n = 100); among 93 children in this subgroup who had repeat serology performed, 86 (92%) demonstrated serologic evidence of HBV protection.
Conclusions: A multidisciplinary approach applying QI methodology allowed for improved and sustained HBV vaccination rates in at-risk seronegative children and adolescents with IBD. A three-dose HBV vaccine series proved immunogenic in 92% of eligible patients.